Targeted Therapy for Non-Small Cell Lung Cancer / 대한내과학회지
Korean Journal of Medicine
;
: 78-88, 2020.
Artigo
| WPRIM
| ID: wpr-836639
ABSTRACT
Treatment of progressive non-small cell lung cancer (NSCLC) has advanced remarkably, due in part to the development of targeted therapies. Several gene alterations, including EGFR, ALK, ROS1, and BRAF, play important roles in carcinogenesis. Therefore, many targeted agents focusing these gene alterations have been developed and proving their therapeutic efficacies in many clinical trials. Now we should test these gene mutations and should apply treatments individually and properly to ensure the maximal survival benefit of each patient. In this review, we summarize the target genes and respective therapeutic agents in NSCLC.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Revista:
Korean Journal of Medicine
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS